Explore the words cloud of the UM Cure 2020 project. It provides you a very rough idea of what is the project "UM Cure 2020" about.
The following table provides information about the project.
|Coordinator Country||France [FR]|
|Total cost||7˙971˙101 €|
|EC max contribution||6˙183˙456 € (78%)|
1. H2020-EU.3.1. (SOCIETAL CHALLENGES - Health, demographic change and well-being)
|Duration (year-month-day)||from 2016-01-01 to 2020-12-31|
Take a look of project's partnership.
|1||INSTITUT CURIE||FR (PARIS)||coordinator||1˙659˙000.00|
|2||ACADEMISCH ZIEKENHUIS LEIDEN||NL (LEIDEN)||participant||1˙021˙540.00|
|3||THE UNIVERSITY OF MANCHESTER||UK (MANCHESTER)||participant||993˙956.00|
|4||PAMGENE INTERNATIONAL BV||NL (DEN HAAG)||participant||469˙625.00|
|5||UNIVERSITEIT LEIDEN||NL (LEIDEN)||participant||434˙376.00|
|6||THE UNIVERSITY OF LIVERPOOL||UK (LIVERPOOL)||participant||358˙604.00|
|7||UNIVERSITA DEGLI STUDI DI TRENTO||IT (TRENTO)||participant||304˙187.00|
|8||FUNDACAO D. ANNA SOMMER CHAMPALIMAUD E DR. CARLOS MONTEZ CHAMPALIMAUD||PT (LISBOA)||participant||248˙750.00|
|9||SEEDING SCIENCE||FR (PARIS)||participant||216˙875.00|
|10||UNIWERSYTET JAGIELLONSKI||PL (Kraków)||participant||213˙792.00|
|11||PEP THERAPY||FR (EVRY)||participant||191˙500.00|
|12||MELANOMA PATIENT NETWORK EUROPE||SE (UPPSALA)||participant||61˙250.00|
|13||KARLSRUHER INSTITUT FUER TECHNOLOGIE||DE (KARLSRUHE)||participant||10˙000.00|
Uveal melanoma (UM) is a rare intraocular tumour with an incidence of 5 cases per million individuals per year. Up to 50% of UM patients develop metastases, most often in the liver, and these are invariably fatal. Despite new discoveries in the genetic and molecular background of the primary tumour, little is known about the metastatic disease; furthermore, there is no therapy to either prevent or treat UM metastases. In UM Cure 2020, we aim to identify and validate at the preclinical level novel therapeutic approaches for the treatment of UM metastases. For this purpose, the consortium brings together the major experts of UM in both patient care and basic/translational/clinical research, as well as patient representatives. An ambitious multidisciplinary approach is proposed to move from patient tissue characterisation to preclinical evaluation of single or combinations of drugs. This approach includes the characterisation of the genetic landscape of metastatic UM and its microenvironment, proteomic studies to address signal pathway deregulation and establishment of novel relevant in vitro and in vivo UM models. We also aim to validate accurate surrogate endpoint biomarkers to evaluate therapies and detect metastases as early as possible. Underpinning this will be the UM Cure 2020 virtual biobank registry, linking existing biobanks into a harmonised network, which will prospectively collect primary and metastatic UM samples. Together, our approach will lead to the identification of new therapies, allowing the initiation of UM-dedicated clinical trials sponsored by academia or pharma. Dissemination of results will include the building of a patient network across the countries as part of the consortium as well as a dedicated UM patient and caregiver’s data portal as part of the UM Cure 2020 website, in order to increase patient information and disease awareness.
Work performed, outcomes and results: advancements report(s)
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "UM CURE 2020" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (firstname.lastname@example.org) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "UM CURE 2020" are provided by the European Opendata Portal: CORDIS opendata.
eHealth Week 2016Read More
High Level eHealth Conference 2015Read More
Develop and validate appropriate and acceptable outcome measures in intermediate age-related macular degeneration for future interventional clinical trials - Sofia ref.: 116076Read More